Literature DB >> 19719975

Thrice-daily biphasic insulin aspart 30 may be another therapeutic option for Chinese patients with type 2 diabetes inadequately controlled with oral antidiabetic agents.

Wen-ying Yang1, Qiu-he Ji, Da-long Zhu, Jin-kui Yang, Lu-lu Chen, Zhi-min Liu, De-min Yu, Li Yan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19719975

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN： 0366-6999            Impact factor:   2.628


× No keyword cloud information.
  3 in total

1.  A crossover study of the combination therapy of metformin and exenatide or biphasic insulin aspart 30 in overweight or obese patients newly diagnosed with type 2 diabetes mellitus.

Authors:  Huibiao Quan; Huachuan Zhang; Weiping Wei; Tuanyu Fang; Daoxiong Chen; Kaining Chen
Journal:  Exp Ther Med       Date:  2017-08-02       Impact factor: 2.447

Review 2.  Diabetes: glycaemic control in type 2 (drug treatments).

Authors:  Kees J Gorter; Floris Alexander van de Laar; Paul G H Janssen; Sebastian T Houweling; Guy E H M Rutten
Journal:  BMJ Clin Evid       Date:  2012-10-11

Review 3.  Ten years of experience with biphasic insulin aspart 30: from drug development to the latest clinical findings.

Authors:  Andreas Liebl; Vinay Prusty; Paul Valensi; Ryuzo Kawamori; Jens Sandahl Christiansen; Andrew J Palmer; Per Balschmidt; Robert Ligthelm; Viswanathan Mohan
Journal:  Drugs       Date:  2012-07-30       Impact factor: 9.546
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.